Dr. Denise C. Daniel, MD, MPH
General Practice (General Practice Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
General Practice Physician primary
PA license MD456007 -
Emergency Medicine Physician
WV license 23331 -
Family Medicine Physician
WV license 23331
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Daytona Beach, FL | 294 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Daytona Beach, FL | 241 |
| Alprazolam Other prescribers in Daytona Beach, FL | 167 |
| Oxycodone Hcl Other prescribers in Daytona Beach, FL | 160 |
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Daytona Beach, FL | 149 |
| Gabapentin Other prescribers in Daytona Beach, FL | 147 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Daytona Beach, FL | 108 |
| Clonazepam Other prescribers in Daytona Beach, FL | 76 |
| Zolpidem Tartrate Other prescribers in Daytona Beach, FL | 64 |
| Methadone Hcl Other prescribers in Daytona Beach, FL | 58 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $82,496 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc. - A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396236 - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396574
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.